We are live on ! Find out more
OC

Oppenheimer & Co Portfolio holdings

AUM $8.21B
1-Year Est. Return 28.81%
This Fund
S&P 500
This Quarter Est. Return
-0.18%
1 Year Est. Return
+28.81%
3 Year Est. Return
+92.54%
5 Year Est. Return
+114.67%
10 Year Est. Return
+429.8%
AUM
$5.34B
AUM Growth
-$237M
Cap. Flow
-$130M
Cap. Flow %
-2.43%
Top 10 Hldgs %
17.36%
Holding
1,615
New
114
Increased
629
Reduced
604
Closed
130

Top Sells

Rank Stock Value
1
MSFT icon
Microsoft
MSFT
+$17.6M
2
AAPL icon
Apple
AAPL
+$16.6M
3
NVDA icon
NVIDIA
NVDA
+$14.2M
4
IDXX icon
Idexx Laboratories
IDXX
+$13.7M
5
XPO icon
XPO
XPO
+$13.2M

Sector Composition

Rank Sector Weight
1 Technology 18.05%
2 Financials 11.09%
3 Healthcare 10.47%
4 Consumer Discretionary 9.45%
5 Industrials 8.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
EIGR
1451
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$100K ﹤0.01%
501
SDC
1452
DELISTED
SmileDirectClub, Inc. Class A Common Stock
SDC
$97K ﹤0.01%
+18,163
New +$113K
GEG icon
1453
Great Elm Group
GEG
$68.4M
$94K ﹤0.01%
41,911
CFMS
1454
DELISTED
Conformis, Inc. Common Stock
CFMS
$93K ﹤0.01%
2,810
-1,600
-36% -$56.4K
RZLT icon
1455
Rezolute
RZLT
$470M
$92K ﹤0.01%
+12,281
New +$124K
SEED icon
1456
Origin Agritech
SEED
$12.1M
$85K ﹤0.01%
+10,450
New +$97.7K
AQB icon
1457
AquaBounty Technologies
AQB
$4.68M
$83K ﹤0.01%
+1,024
New +$95.9K
FPL
1458
DELISTED
FIRST TRUST NEW OPPORTUNITIES MLP & ENERGY FUND
FPL
$78K ﹤0.01%
13,658
+105
+0.8% +$600
TRIT
1459
DELISTED
Triterras, Inc. Class A Ordinary Shares
TRIT
$76K ﹤0.01%
12,974
-524
-4% -$2.85K
VANI icon
1460
Vivani Medical
VANI
$112M
$73K ﹤0.01%
+7,671
New +$86.4K
TOON icon
1461
Kartoon Studios
TOON
$35.1M
$72K ﹤0.01%
5,319
+4,139
+351% +$64.4K
BRW
1462
Saba Capital Income & Opportunities Fund
BRW
$342M
$70K ﹤0.01%
7,730
-4,804
-38% -$44.1K
MLSS icon
1463
Milestone Scientific
MLSS
$34.6M
$70K ﹤0.01%
37,500
+2,000
+6% +$3.7K
VCNX
1464
DELISTED
Vaccinex, Inc. Common Stock
VCNX
$69K ﹤0.01%
151
-49
-25% -$24.4K
CBUS icon
1465
Cibus
CBUS
$147M
$65K ﹤0.01%
385
-109
-22% -$21.1K
FAX
1466
abrdn Asia-Pacific Income Fund
FAX
$597M
$63K ﹤0.01%
2,500
-3,333
-57% -$85.5K
AEG icon
1467
Aegon
AEG
$14B
$52K ﹤0.01%
10,752
-207
-2% -$897
SENS icon
1468
Senseonics Holdings Inc
SENS
$265M
$51K ﹤0.01%
750
WPRT
1469
Westport Fuel Systems
WPRT
$32.7M
$50K ﹤0.01%
1,550
-487
-24% -$19.6K
SBEV icon
1470
Splash Beverage Group
SBEV
$2.17M
$47K ﹤0.01%
+146
New +$66K
MREO
1471
Mereo BioPharma
MREO
$50.3M
$46K ﹤0.01%
+19,000
New +$50.3K
AMPE
1472
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
$42K ﹤0.01%
84
AUY
1473
DELISTED
Yamana Gold, Inc.
AUY
$41K ﹤0.01%
+10,408
New +$44.1K
NBSE
1474
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$37K ﹤0.01%
518
-120
-19% -$9.18K
LYG icon
1475
Lloyds Banking Group
LYG
$90.7B
$34K ﹤0.01%
+13,901
New +$34.1K

Similar funds

Oppenheimer & Co's Q3 2021 Portfolio in Review

As of Q3 2021, Oppenheimer & Co held 1,615 positions worth $5.34B, down 4.2% from $5.58B the previous quarter. Its ten largest holdings account for 17% of the portfolio.

Oppenheimer & Co's Q3 2021 filing shows 114 new, 629 increased, 604 reduced and 130 closed positions. Its largest new stake was Global X S&P 500 Covered Call ETF: 1,004,600 shares worth $488K. The largest sale was Microsoft, an estimated $17.6M.

By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 18% a quarter earlier, followed by Financials and Healthcare.

  • Oppenheimer & Co's largest Q3 2021 buy was Global X S&P 500 Covered Call ETF: 1,004,600 shares worth $488K.
  • Oppenheimer & Co added most to Invesco Ultra Short Duration ETF in Q3 2021, an estimated $9.29M increase.
  • Oppenheimer & Co's biggest Q3 2021 reduction was Microsoft, cutting an estimated $17.6M.
  • Oppenheimer & Co fully exited Pricesmart in Q3 2021, selling an estimated $6.18M.
  • Oppenheimer & Co's ten largest holdings make up 17% of its $5.34B portfolio in Q3 2021.
  • Oppenheimer & Co opened 114 new positions and closed 130 in Q3 2021.
  • Oppenheimer & Co's portfolio value fell 4.2% quarter-over-quarter to $5.34B.

Based on Oppenheimer & Co's 13F filing for Q3 2021, filed 12 Nov 2021.